Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:OSMT

Osmotica Pharmaceuticals (OSMT) Stock Price, News & Analysis

Osmotica Pharmaceuticals logo

About Osmotica Pharmaceuticals Stock (NASDAQ:OSMT)

Key Stats

Today's Range
N/A
50-Day Range
$0.98
$1.49
52-Week Range
N/A
Volume
296,500 shs
Average Volume
396,682 shs
Market Capitalization
$69.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.

Receive OSMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Osmotica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OSMT Stock News Headlines

Vanda Pharmaceuticals Inc.
RVL Pharmaceuticals PLC (RVLPQ)
2024 Election Year Stocks: Uncover Hidden Gems!
In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.
What Wall Street expects from Osmotica Pharmaceuticals's earnings
See More Headlines

OSMT Stock Analysis - Frequently Asked Questions

Osmotica Pharmaceuticals plc (NASDAQ:OSMT) posted its earnings results on Monday, November, 15th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.06. The firm earned $2.20 million during the quarter, compared to analyst estimates of $2.39 million. Osmotica Pharmaceuticals had a negative net margin of 138.76% and a negative trailing twelve-month return on equity of 81.23%.

Osmotica Pharmaceuticals (OSMT) raised $58 million in an initial public offering on Thursday, October 18th 2018. The company issued 8,300,000 shares at $7.00 per share. Jefferies, Barclays, RBC Capital MarketsWells and Fargo Securities acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Osmotica Pharmaceuticals investors own include Canopy Growth (CGC), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), NIO (NIO), Allena Pharmaceuticals (ALNA) and Endo International (ENDP).

Company Calendar

Last Earnings
11/15/2021
Today
11/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OSMT
Fax
N/A
Employees
302
Year Founded
N/A

Profitability

Net Income
$-79,590,000.00
Net Margins
-138.76%
Pretax Margin
-167.59%

Debt

Sales & Book Value

Annual Sales
$177.88 million
Book Value
$1.50 per share

Miscellaneous

Free Float
59,318,000
Market Cap
$69.47 million
Optionable
Not Optionable
Beta
2.34
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:OSMT) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners